Bio-equivalent drugs helps NHI finance saving.

Published: 2004-07-27 06:59:00

Updated: 2004-07-27 06:59:00

An increased number of drugs proven of its bio-equivalency to the original drugs and due extended scope of physician's prescriptions have greatly contributed to save the National Health Insurance (NHI) fund

The pharmaceutical industry reported that number of drugs proven of its bio-equivalenc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK